These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
243 related articles for article (PubMed ID: 34894841)
1. The impact of cumulative colorectal cancer screening delays: A simulation study. Rutter CM; Inadomi JM; Maerzluft CE J Med Screen; 2022 Jun; 29(2):92-98. PubMed ID: 34894841 [TBL] [Abstract][Full Text] [Related]
2. Screening for Colorectal Cancer With Fecal Immunochemical Testing With and Without Postpolypectomy Surveillance Colonoscopy: A Cost-Effectiveness Analysis. Greuter MJE; de Klerk CM; Meijer GA; Dekker E; Coupé VMH Ann Intern Med; 2017 Oct; 167(8):544-554. PubMed ID: 28973514 [TBL] [Abstract][Full Text] [Related]
3. Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test. Meester RG; Zauber AG; Doubeni CA; Jensen CD; Quinn VP; Helfand M; Dominitz JA; Levin TR; Corley DA; Lansdorp-Vogelaar I Clin Gastroenterol Hepatol; 2016 Oct; 14(10):1445-1451.e8. PubMed ID: 27211498 [TBL] [Abstract][Full Text] [Related]
4. Population health outcomes of blood-based screening for colorectal cancer in comparison to current screening modalities: insights from a discrete-event simulation model incorporating longitudinal adherence. Forbes SP; Yay Donderici E; Zhang N; Sharif B; Tremblay G; Schafer G; Raymond VM; Talasaz A; Eagle C; Das AK; Grady WM J Med Econ; 2024; 27(1):991-1002. PubMed ID: 39037853 [TBL] [Abstract][Full Text] [Related]
5. Optimal use of colonoscopy and fecal immunochemical test for population-based colorectal cancer screening: a cost-effectiveness analysis using Japanese data. Sekiguchi M; Igarashi A; Matsuda T; Matsumoto M; Sakamoto T; Nakajima T; Kakugawa Y; Yamamoto S; Saito H; Saito Y Jpn J Clin Oncol; 2016 Feb; 46(2):116-25. PubMed ID: 26685321 [TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness and budget impact analyses of colorectal cancer screenings in a low- and middle-income country: example from Thailand. Phisalprapa P; Supakankunti S; Chaiyakunapruk N J Med Econ; 2019 Dec; 22(12):1351-1361. PubMed ID: 31560247 [No Abstract] [Full Text] [Related]
7. Quantifying the impact of adherence to screening strategies on colorectal cancer incidence and mortality. D'Andrea E; Ahnen DJ; Sussman DA; Najafzadeh M Cancer Med; 2020 Jan; 9(2):824-836. PubMed ID: 31777197 [TBL] [Abstract][Full Text] [Related]
8. Colorectal cancer screening with faecal immunochemical testing, sigmoidoscopy or colonoscopy: a microsimulation modelling study. Buskermolen M; Cenin DR; Helsingen LM; Guyatt G; Vandvik PO; Haug U; Bretthauer M; Lansdorp-Vogelaar I BMJ; 2019 Oct; 367():l5383. PubMed ID: 31578177 [TBL] [Abstract][Full Text] [Related]
9. Rescreening of persons with a negative colonoscopy result: results from a microsimulation model. Knudsen AB; Hur C; Gazelle GS; Schrag D; McFarland EG; Kuntz KM Ann Intern Med; 2012 Nov; 157(9):611-20. PubMed ID: 23128861 [TBL] [Abstract][Full Text] [Related]
10. Colorectal Cancer Screening: An Updated Modeling Study for the US Preventive Services Task Force. Knudsen AB; Rutter CM; Peterse EFP; Lietz AP; Seguin CL; Meester RGS; Perdue LA; Lin JS; Siegel RL; Doria-Rose VP; Feuer EJ; Zauber AG; Kuntz KM; Lansdorp-Vogelaar I JAMA; 2021 May; 325(19):1998-2011. PubMed ID: 34003219 [TBL] [Abstract][Full Text] [Related]
11. Fecal occult blood test for colorectal cancer screening: an evidence-based analysis. Medical Advisory Secretariat Ont Health Technol Assess Ser; 2009; 9(10):1-40. PubMed ID: 23074514 [TBL] [Abstract][Full Text] [Related]
12. Characteristics of a cost-effective blood test for colorectal cancer screening. Nascimento de Lima P; van den Puttelaar R; Knudsen AB; Hahn AI; Kuntz KM; Ozik J; Collier N; Alarid-Escudero F; Zauber AG; Inadomi JM; Lansdorp-Vogelaar I; Rutter CM J Natl Cancer Inst; 2024 Oct; 116(10):1612-1620. PubMed ID: 38845072 [TBL] [Abstract][Full Text] [Related]
13. Health benefits and cost-effectiveness of a hybrid screening strategy for colorectal cancer. Dinh T; Ladabaum U; Alperin P; Caldwell C; Smith R; Levin TR Clin Gastroenterol Hepatol; 2013 Sep; 11(9):1158-66. PubMed ID: 23542330 [TBL] [Abstract][Full Text] [Related]
14. The impact of the rising colorectal cancer incidence in young adults on the optimal age to start screening: Microsimulation analysis I to inform the American Cancer Society colorectal cancer screening guideline. Peterse EFP; Meester RGS; Siegel RL; Chen JC; Dwyer A; Ahnen DJ; Smith RA; Zauber AG; Lansdorp-Vogelaar I Cancer; 2018 Jul; 124(14):2964-2973. PubMed ID: 29846933 [TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness analysis of colorectal cancer screening using colonoscopy, fecal immunochemical test, and risk score. Sekiguchi M; Igarashi A; Sakamoto T; Saito Y; Esaki M; Matsuda T J Gastroenterol Hepatol; 2020 Sep; 35(9):1555-1561. PubMed ID: 32167186 [TBL] [Abstract][Full Text] [Related]
16. Lowering the colorectal cancer screening age improves predicted outcomes in a microsimulation model. Fisher DA; Saoud L; Finney Rutten LJ; Ozbay AB; Brooks D; Limburg PJ Curr Med Res Opin; 2021 Jun; 37(6):1005-1010. PubMed ID: 33769894 [TBL] [Abstract][Full Text] [Related]
17. Analysis of the effectiveness of two noninvasive fecal tests used to screen for colorectal cancer in average-risk adults. Sharma T Public Health; 2020 May; 182():70-76. PubMed ID: 32179290 [TBL] [Abstract][Full Text] [Related]
18. A combination of clinical risk stratification and fecal immunochemical test is useful for identifying persons with high priority of early colonoscopy. Jung YS; Park CH; Kim NH; Park JH; Park DI; Sohn CI Dig Liver Dis; 2018 Mar; 50(3):254-259. PubMed ID: 29198569 [TBL] [Abstract][Full Text] [Related]